- NYSE: ABT is on course to leap by around 10% on Thursday.
- Abbott Laboratories has received an FDA approval for its BinaxNOW COVID-19 Card test.
- The rapid, cheap, and instrument-free probe is touted as a game-changer.
A game-changer in fighting coronavirus – and this time it is not a vaccine or a cure, but a rapid test coming from a well-established company. Abbott Laboratories (NYSE: ABT) may now begin selling its Aboott BinaxNow COVID-19 Ag Card Test. The Food and Drug Administration (FDA) has given its emergency authorization, allowing mass production of the test.
Abbott expects to manufacture around ten million units in September, 50 million in October, and continue ramping up output later on. The Chicago-based firm – which is in businesses since the 19th century – said that results of the test are out after 15 minutes – far faster than the standard PCR ones.
Abbott Laboratories also said that the tests have a demonstrated sensitivity of 97.1% and specificity of 98.5% in a clinical study. The tests are also cheap – only $5, and do not necessitate any labs or instruments.
Using such rapid tests could help capture asymptomatic COVID-19 carriers and isolate them before they infect others. Moreover, it could allow a quick resumption of normal life. Air passengers can undergo these quick tests, assuring with a high degree of certainty that no coronavirus-carrying patient is on board.
Overall, the product is promising.
ABT Stock Dividend
NYSE: ABT is changing hands at over $112 in pre-market trading on Thursday, an increase of nearly 10%. It is critical to note that Abbott Laboratories is a large pharmaceutical firm worth over $180 billion, and such a move is substantial.
Moreover, sales of BinaxNOW could boost income and the bottom line, leading to a higher dividend. The mere prospects of topping its 2019 revenue of $31.9 billion could also trigger an increase in Abbott's payout to shareholders.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds above 1.0650 after US data
EUR/USD retreats from session highs but manages to hold above 1.0650 in the early American session. Upbeat macroeconomic data releases from the US helps the US Dollar find a foothold and limits the pair's upside.
GBP/USD retreats toward 1.2450 on modest USD rebound
GBP/USD edges lower in the second half of the day and trades at around 1.2450. Better-than-expected Jobless Claims and Philadelphia Fed Manufacturing Index data from the US provides a support to the USD and forces the pair to stay on the back foot.
Gold is closely monitoring geopolitics
Gold trades in positive territory above $2,380 on Thursday. Although the benchmark 10-year US Treasury bond yield holds steady following upbeat US data, XAU/USD continues to stretch higher on growing fears over a deepening conflict in the Middle East.
Ripple faces significant correction as former SEC litigator says lawsuit could make it to Supreme Court
Ripple (XRP) price hovers below the key $0.50 level on Thursday after failing at another attempt to break and close above the resistance for the fourth day in a row.
Have we seen the extent of the Fed rate repricing?
Markets have been mostly consolidating recent moves into Thursday. We’ve seen some profit taking on Dollar longs and renewed demand for US equities into the dip. Whether or not this holds up is a completely different story.